Evaluation of muvalaplin versus placebo for the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) and established or high risk of cardiovascular disease. The study examines whether lowering Lp(a) can reduce the risk of heart attack, stroke, and cardiovascular procedures.
This research study is designed to find out whether muvalaplin, compared to a placebo, can reduce the likelihood of major cardiovascular events — such as heart attack, stroke, or procedures to restore blood flow — in adults who have high Lp(a) levels and either existing heart disease or risk factors for it.
High Lp(a) is a type of cholesterol-related particle in the blood that is mostly determined by genetics and remains relatively stable throughout life. Elevated Lp(a) has been linked with plaque buildup in the arteries, which increases cardiovascular risk even when other lipid levels are treated.
How the study works:
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial — meaning participants are randomly assigned to receive either muvalaplin or a placebo, and neither you nor the study team will know which one you’re getting during the study.
Adults 18 years and older with high Lp(a) (≥ 175 nmol/L) and cardiovascular disease or risk factors may be eligible.
Everyone in the study continues to receive their regular medical care.
The study plans to enroll about 10,450 participants worldwide and is expected to continue for several years, with an estimated completion around March 2031.
Why join?
Participation in this study may help advance research into whether lowering elevated lipoprotein(a) can reduce the risk of serious heart and blood vessel events. You will receive study-related medical care at no cost from our research team and may be compensated for your time and travel.
Adults 18+
All genders welcome
High Lp(a) (≥ 175 nmol/L) and cardiovascular disease.
Daytona Beach, FL
Fill out the form below to see if you qualify for our heart & kidney health study in Daytona Beach. Participation is completely voluntary, and all study-related care will be provided at no cost to you.
Why Join?
Participating in a clinical trial at Arrow Clinical Trials in Daytona Beach, is an opportunity to take charge of your health while helping advance medical science. All while under the care of experienced local physicians.
Evaluation of muvalaplin versus placebo for the reduction of major adverse cardiovascular events in adults with elevated lipoprotein(a) and established or high risk of cardiovascular disease. The study examines whether lowering Lp(a) can reduce the risk of heart attack, stroke, and cardiovascular procedures.
We currently conduct research studies in Hypertension, Orthopedics, Cardiology, and Neurology.
Our trials include treatments for high blood pressure, joint pain, heart health, stroke recovery, migraines, and other conditions affecting the brain and nervous system.
No. All studies at Arrow Clinical Trials are provided at no cost to participants, and insurance is not required.
Any procedures, tests, or study-related care will be covered by the trial sponsor.
Yes. Participants may receive compensation for their time and travel. The exact amount depends on the study and the number of visits required.
Each study has specific requirements, such as age range, medical history, and current health status.
Our research team will review your information and conduct a screening process to determine if you qualify.